Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Bub1 Monoclonal Antibody (14H5)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA15755
Description
MA1-5755 detects BUB1 in Human samples and is predicted to detect BUB1 in Rat, Xenopus laevis, and Kangaroo. MA1-5755 has been successfully used in immunofluorescence and immunoprecipitation procedures.
BUB1A is a kinase involved in spindle checkpoint function. The kinase functions in part by phosphorylating a member of the miotic checkpoint complex and activating the spindle checkpoint.
Specifications
Bub1 | |
Monoclonal | |
1.1 mg/mL | |
PBS with 0.1% sodium azide | |
O08901, O43683 | |
BUB1 | |
Fusion protein, corresponding to amino acids 281-419 of Human Bub 1. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG1 |
Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
14H5 | |
Unconjugated | |
BUB1 | |
Aamp; Aamp-rs; AL022991; angio associated migratory cell protein; angio-associated migratory cell protein; angio-associated migratory protein; angio-associated, migratory cell protein; AU040907; BUB1; BUB1 budding uninhibited by benzimidazoles 1 homolog; BUB1 mitotic checkpoint serine/threonine kinase; BUB1, mitotic checkpoint serine/threonine kinase; BUB1A; BUB1L; budding uninhibited by benzimidazoles 1 homolog; budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae); C80208; D2Xrf87; hBUB1; mBUB1; mitotic checkpoint serine/threonine-protein kinase BUB1; mitotic spindle checkpoint kinase; putative serine/threonine-protein kinase | |
Mouse | |
Protein A | |
RUO | |
12235, 699 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction